Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 53, 2019 - Issue 4
Journal homepage
149
Views
2
CrossRef citations to date
0
Altmetric
Article

A Nordic registry-based study of drug treatment patterns in overactive bladder patients

Ian MilsomDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Correspondence[email protected]
View further author information
,
Hjalmar A. SchiotzDepartment of Obstetrics & Gynecology, Vestfold Hospital Trust, Tønsberg, Norway; View further author information
,
Maja SvenssonDepartment of Medical Affairs, Astellas Pharma A/S, Kastrup, Denmark; View further author information
,
Suzanne KilanyDepartment of Medical Affairs, Astellas Pharma A/S, Kastrup, Denmark; View further author information
&
Fredrik HanssonDepartment of Biometrics, CTC Clinical Trial Consultants AB, Uppsala, SwedenView further author information
Pages 246-254 | Received 11 Mar 2019, Accepted 13 May 2019, Published online: 14 Jun 2019

References

  • Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59:931–937.
  • Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314.
  • Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–1138.
  • Nordic Council of Ministers. Nordic Statistics 2016 [accessed 2017 Oct 3]. Available at: http://norden.diva-portal.org/smash/record.jsf?pid=diva2%3A1040725&dswid=-2515.
  • Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–1774.
  • Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191:1003–1008.
  • Kim TH, Lee KS. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57:84–93.
  • D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14:291–301.
  • Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005;11:S121–S129.
  • Kato D, Uno S, Van Schyndle J, et al. Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis. Int J Urol. 2017;24:757–764.
  • Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–562.
  • Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295.
  • Altman D, Granath F, Mattiasson A, et al. Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. Int Urogynecol J. 2009;20:1285–1291.
  • Socialstyrelsen. The Swedish National Board of Health and Welfare [accessed 2017 Oct 18]. Available at: http://www.socialstyrelsen.se/english.
  • The Danish Health Data Authority. Medstat.dk [accessed 2017 Oct 18]. Available at: http://www.medstat.dk/en.
  • Norwegian Institute of Public Health. The Norwegian prescription database [accessed 2017 Oct 18]. Available at: http://www.norpd.no/.
  • Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65:309–314.
  • Linner L, Schioler H, Samuelsson E, et al. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol. 2011;67:535–536.
  • Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand. 2013;92:1208–1215.
  • Statens Serum Institute. Statens Serum Institute [accessed 2017 Oct 23]. Available at: https://www.ssi.dk/English.aspx.
  • Norwegian Institute of Public Health. Norwegian Institute of Public Health [accessed 2017 Oct 23]. Available at: https://www.fhi.no/en/.
  • Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–399.
  • Nitti VW, Rovner ES, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits 2016;8:e25–e33.
  • Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9:343–350.
  • Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn. 2017;36:404–408.
  • Wagg A. Persistence with medication and overactive bladder: an ongoing challenge. Expert Rev Pharmacoecon Outcomes Res. 2016;16:475–481.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.